Pos-192 efficacy of febuxostat in retarding progression of chronic kidney disease with assymptomatic hyperuricaemia

Asymptomatic hyperuricemia is commonly viewed as an entity that should not be treated. Treatment of asymptomatic hyperuricemia in patients with renal impairment is still in debate.There is no evidence to rationalize pharmacotherapy for patients with hyperuricemia with no complication and serum uric acid (SUA) concentration is below 10 mg/dL. Our objective isto evaluate the efficacy of febuxostat in retarding the progression of chronic kidney disease (stages 3 and 4) with asymptomatic hyperuricemia.